Abstract： Objective:To systematically evaluate the clinical efficacy and cost-effectiveness of Shufeng Jiedu(疏风解毒)Capsules(SFJDC)com-bined with conventional western medicine versus conventional western medicine alone in the treatment of acute exacerbation of chronic ob-structive pulmonary disease(AECOPD).Methods:China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,PubMed,and EMbase were searched from database inception to June 2023.Following inclusion and exclusion criteria,literature was screened,and data were extracted.Meta-analysis and cost-effectiveness analysis were conducted to evaluate the clinical efficacy and cost-effectiveness of the two treat-ment regimens for AECOPD.Results:Clinical efficacy:The total effective rates of SFJDC combined with conventional therapy and convention-al therapy alone in treating AECOPD were 88.43％and 73.69％,respectively,with no significant difference in safety.Cost-effectiveness:Cost-effectiveness analysis of the total effective rate for hospitalized and non-hospitalized AECOPD patients treated with SFJDC combined ther-apy versus conventional therapy revealed that the cost-effectiveness ratio(CER)of the SFJDC combined therapy group was lower than that of the conventional therapy group,indicating that the SFJDC combined therapy was more cost-effective.Sensitivity analysis results were robust.Conclusion:SFJDC combined with conventional therapy is superior to conventional therapy alone in terms of both clinical efficacy and cost-ef-fectiveness in the treatment of AECOPD,making it an advantageous treatment regimen.